A US-based KOL provides insights into prescribing habits, key marketed brands, and late-phase pipeline therapies for HER2+ breast cancer. Key pipeline assets highlighted include Enhertu, Tecentriq, Piqray, and Tukysa.

This interview was conducted on 21 July 2023.

If you are a KOL Insight Subscriber, please access the interview from our KOL Insight portal (Subscribers only).

Biomedtracker's KOL Insight transcripts are available through subscription only. For more information on obtaining a KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (888) 670-8900.

For our disclosures, please read the Biomedtracker Research Standards.